PharmaPoint:偏頭痛 - 美國的醫藥品的預測與市場分析
PharmaPoint: Migraine - US Drug Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 143 Pages
|PharmaPoint:偏頭痛 - 美國的醫藥品的預測與市場分析 PharmaPoint: Migraine - US Drug Forecast and Market Analysis to 2023|
|出版日期: 2014年03月31日||內容資訊: 英文 143 Pages||
The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.
The US migraine market is the largest given its population size and high drug prices. The main growth driver during this period will be Allergan's Botox, in addition to the launch of new combinations of drug and device and new classes of acute therapy. Historically the triptans have dominated the acute migraine segment and although the gold standard, GSK's Imitrex, expired in 2008, it has remained as one of the most popular triptans among physicians. A recent trend in this segment is the development of devices that can deliver drugs in a more effective way, such as Sumavel DosePro, a needle-free injection of sumatriptan.